Home・Listă Acțiuni・Glaukos Corp

Glaukos Corp

Închisă

SectorSănătate

179.18 4.99

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

170.88

Maxim

180.24

Indicatori cheie
By Trading Economics
Venit	1.4M -18M
Vânzări	35M 186M
EPS	-0.14
Marjă de profit	-9.901
Angajați	1,094
EBITDA	-11M -16M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+3.83% upside

Dividende
By Acuity
Următoarele câștiguri	28 oct. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	1.2B 10B
Deschiderea anterioară	174.19
Închiderea anterioară	179.18

Sentimentul știrilor

By Acuity

41%

59%

124 / 340 Clasament în Healthcare

Glaukos Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

7 aug. 2026, 20:02 UTC

Glaukos Corp shares are rising in Friday's session, supported by unusually high trading volume and a steady upward trend since Thursday's close.

4 aug. 2026, 19:36 UTC

Glaukos Corp shares are lower today, impacted by declines in the Health Care Equipment sub-sector. The stock pulled back after reaching an earlier high.

3 aug. 2026, 20:06 UTC

Glaukos Corp shares are higher amid positive market sentiment, with the S&P 500 and Nasdaq 100 also gaining. The stock remains above its 20-day moving average.

31 iul. 2026, 19:45 UTC

News

Glaukos shares are lower today despite H.C. Wainwright raising the price target to $195 from $168. Trading volume has been unusually high.

30 iul. 2026, 21:31 UTC

News

Glaukos Corp shares are lower in after-market trading, tracking declines in the Health Care Equipment sector. UBS raised its price target to $172.

29 iul. 2026, 21:22 UTC

Social Media

News

Glaukos Corp reported record net sales of $185.6 million in Q2 2026, raising its full-year revenue guidance to $680 million to $700 million. Shares are higher in after-market trading.

28 iul. 2026, 17:46 UTC

News

Glaukos Corp shares are lower after UBS initiated coverage with a Neutral rating, overshadowing Stifel's Buy rating and $175 price target.

27 iul. 2026, 19:16 UTC

Glaukos Corp shares are lower today, despite an initial gain. Broader market trends are affected by a significant drop in oil prices.

24 iul. 2026, 19:56 UTC

Glaukos Corp. shares are trading higher today, maintaining a cumulative gain since Thursday and remaining above their 20-day moving average.

21 iul. 2026, 17:41 UTC

Glaukos Corp shares are lower today amid a decline in the Health Care Equipment sub-sector, reversing the recent trend of higher daily closes.

Comparație

Modificare preț

Glaukos Corp Așteptări

Obiectiv de preț

By TipRanks

3.83% sus

Prognoză pe 12 luni

Medie 186.92 USD 3.83%

Maxim 215 USD

Minim 153 USD

În baza a 14 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruGlaukos Corp - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

14 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 14 analiști care au acordat evaluări ale acțiunilor Glaukos Corp - Dist în ultimele 3 luni.

Sentiment

By Acuity

124 / 340 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Glaukos Corp

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.